CRLBF Stock — Cresco Labs Inc

Cresco Labs Inc (CRLBF)

Updated October 16, 2026.

CRLBF is a Stock. Total return is -88.0% over the past 7.9 years, 296.0 points behind SPY at 208.0%.

Cresco Labs Inc. cultivates, manufactures, and sells cannabis products across multiple brands in the United States and Germany, offering flowers, vape products, edibles, extracts, and oils under brands including Cresco, High Supply, Good News, Wonder Wellness Co., Remedi, FloraCal, Mindy's, Loud*r, and Sunnyside. The company's distribution profile is not currently established. This business appeals to investors seeking exposure to the cannabis industry.

CRLBF performance versus SPY

Price and return data through 2026-10-16.

Total return is -88.0% over the past 7.9 years, 296.0 points behind SPY at 208.0%. Over the past year its total return — price change plus distributions reinvested — is -55.3%. Its deepest 1-year drawdown was 69.0%.

CRLBF key facts

Asset type

Stock

Asset class

Equity

Inception date

12/03/2018

Distribution frequency

None

Last close

$0.59 (as of 2026-10-16)

Market cap

$210,530,416

Average volume

213965.0

Beta

1.811

Payout ratio

0.0%

Forward P/E

105.2632

EPS

$-0.28

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CRLBF risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 69.0%.

Who may consider CRLBF — and who may not

It is a weaker fit for investors who need monthly cash flow (CRLBF does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CRLBF

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions